These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34443682)

  • 1.
    Kamaruddin NN; Hajri NA; Andriani Y; Abdul Manan AF; Tengku Muhammad TS; Mohamad H
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443682
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kamaruddin NN; Mohd Din LH; Jack A; Abdul Manan AF; Mohamad H; Tengku Muhammad TS
    Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
    Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2.
    Chae HS; Pel P; Cho J; Kim YM; An CY; Huh J; Choi YH; Kim J; Chin YW
    J Ethnopharmacol; 2021 Oct; 278():114265. PubMed ID: 34111537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cholesterol-Modulating Effect of Methanol Extract of Pigeon Pea (
    Chang HY; Wu JR; Gao WY; Lin HR; Chen PY; Chen CI; Wu MJ; Yen JH
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30704067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake.
    Lupo MG; Macchi C; Marchianò S; Cristofani R; Greco MF; Dall'Acqua S; Chen H; Sirtori CR; Corsini A; Ruscica M; Ferri N
    Nutr Metab Cardiovasc Dis; 2019 Nov; 29(11):1245-1253. PubMed ID: 31439394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice.
    Xu X; Dong Y; Ma N; Kong W; Yu C; Gong L; Chen J; Ren J
    Metabolism; 2021 Jun; 119():154768. PubMed ID: 33775647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antioxidative and anticancer activities of various ethanolic extract fractions from crown-of-thorns starfish (Acanthaster planci).
    Lee CC; Hsieh HJ; Hsieh CH; Hwang DF
    Environ Toxicol Pharmacol; 2014 Nov; 38(3):761-73. PubMed ID: 25305737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
    Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B
    J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
    Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
    Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication.
    Furuhashi M; Omori A; Matsumoto M; Kataoka Y; Tanaka M; Moniwa N; Ohnishi H; Yoshida H; Saitoh S; Shimamoto K; Miura T
    Am J Cardiol; 2016 Jul; 118(2):198-203. PubMed ID: 27241838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
    Pedro-Botet J; Badimón L
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin nicotinate decreases serum LDL cholesterol through LDL receptor-mediated mechanism.
    Zhang C; Xiang D; Zhao Q; Jiang S; Wang C; Yang H; Huang Y; Yuan Y; Liu X; Huang Z; Zeng Y; Wen H; Long S; Hao H; Tuo Q; Liu Z; Liao D
    Eur J Pharmacol; 2022 Sep; 931():175195. PubMed ID: 35964656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
    Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
    Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlike estrogens that increase PCSK9 levels post-menopause HSP27 vaccination lowers cholesterol levels and atherogenesis due to divergent effects on PCSK9 and LDLR.
    Maarouf N; Chen YX; Shi C; Deng J; Diao C; Rosin M; Shrivastava V; Batulan Z; Liu J; O'Brien ER
    Pharmacol Res; 2020 Nov; 161():105222. PubMed ID: 33022407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.